Vevorisertib
Vevorisertib (ARQ 751) is an orally active, potent and selective pan-AKT serine/threonine kinase inhibitor against AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM) . Vevorisertib, as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations[1][2][3][4].
Product Specifications
Product Name Alternative
ARQ 751
UNSPSC
12352005
Target
Akt; Ser/Thr Protease
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vevorisertib.html
Purity
98.03
Solubility
DMSO : 6.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
NC1=C(C=CC=N1)C2=NC3=CC=C(C4=CC(N(CC5)CCC5N(C)C(C)=O)=CC=C4)N=C3N2C6=CC=C(C7(CCC7)N)C=C6
Molecular Formula
C35H38N8O
Molecular Weight
586.73
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-137458/Vevorisertib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-137458/Vevorisertib-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Akt1; Akt2; Akt3
CAS Number
[1416775-46-6]
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
